Evidence map›Paper›PMID 26602520›Full record

ArticleClinics (Sao Paulo, Brazil)2015

Serum from patients with ankylosing spondylitis can increase PPARD, fra-1, MMP7, OPG and RANKL expression in MG63 cells.

Zaiying Hu, Dongfang Lin, Jun Qi, Minli Qiu, Qing Lv, Qiuxia Li, Zhiming Lin, Zetao Liao, Yunfeng Pan, Ou Jin and 2 more

Open access · goldAbstract read
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Zaiying HuDepartment of Rheumatology, Sun Yat-Sen University, Guangzhou, China.
Dongfang LinDepartment of Rheumatology, Sun Yat-Sen University, Guangzhou, China.
Jun QiDepartment of Rheumatology, Sun Yat-Sen University, Guangzhou, China.
Minli QiuDepartment of Rheumatology, Sun Yat-Sen University, Guangzhou, China.
Qing LvDepartment of Rheumatology, Sun Yat-Sen University, Guangzhou, China.
Qiuxia LiDepartment of Rheumatology, Sun Yat-Sen University, Guangzhou, China.
Zhiming LinDepartment of Rheumatology, Sun Yat-Sen University, Guangzhou, China.
Zetao LiaoDepartment of Rheumatology, Sun Yat-Sen University, Guangzhou, China.
Yunfeng PanDepartment of Rheumatology, Sun Yat-Sen University, Guangzhou, China.
Ou JinDepartment of Rheumatology, Sun Yat-Sen University, Guangzhou, China.
Yuqiong WuDepartment of Rheumatology, Sun Yat-Sen University, Guangzhou, China.
Jieruo GuDepartment of Rheumatology, Sun Yat-Sen University, Guangzhou, China.
Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo explore the effects of serum from patients with ankylosing spondylitis on the canonical Wnt/β-catenin pathway and to assess whether the serum has an osteogenic effect in MG63 cells.

methodsMG63 cells were cultured with serum from 45 ankylosing spondylitis patients, 30 healthy controls, or 45 rheumatoid arthritis patients. The relative PPARD, fra-1, MMP7, OPG and RANKL mRNA levels were measured using quantitative real-time polymerase chain reaction. Associations between gene expression and patient demographics and clinical assessments were then analyzed.

resultsMG63 cells treated with serum from ankylosing spondylitis patients had higher PPARD, fra-1, MMP7 and OPG gene expression than did cells treated with serum from controls or rheumatoid arthritis patients (all p<0.05). RANKL expression was higher in MG63 cells treated with serum from patients with ankylosing spondylitis or rheumatoid arthritis than in those treated with serum from controls (both p<0.05). The OPG/RANKL ratio was also higher in MG63 cells treated with serum from ankylosing spondylitis patients than in those treated with serum from controls (p<0.05). No associations were found between the expression of the five genes and the patient demographics and clinical assessments (all p>0.05).

conclusionsSerum from ankylosing spondylitis patients increases PPARD, fra-1, MMP7, OPG and RANKL expression and the OPG/RANKL ratio in MG63 cells; these effects may be due to the stimulatory effect of the serum on the Wnt pathway.

Indexed as

SerumAdultArthritis, Rheumatoidbeta CateninCells, CulturedCulture MediaCytokinesFemaleFos-Related Antigen 1Gene ExpressionHumansMaleMatrix Metalloproteinase 7Middle AgedOsteoblastsPPAR deltabeta CateninCulture MediaCytokinesFos-Related Antigen 1Matrix Metalloproteinase 7MMP7 protein, humanosteoclastpoietic factorPPAR deltaProto-Oncogene Proteins c-fosRANK Ligand

Identifiers

PMID26602520
PMCPMC4642487
OpenAlexW2177853519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.